Exhibit 10.2

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

--------------------------------------------------------------------------------

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

(International Stem Cell Corporation)

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made
as of the 9th day of March 2012, by and among International Stem Cell
Corporation, a Delaware corporation (the “Company”), AR Partners, LLC, a
Delaware limited liability company, (the “Series G Investor”) and each of the
investors listed on Schedule A of the Investors’ Rights Agreement made as of
December 30, 2008 (each a “Series D Investor” and together with the Series G
Investor, each an “Investor” as set forth on Schedule A hereto)

RECITALS

WHEREAS, the Company and the Series D Investor are parties to the Investors’
Rights Agreement, dated as of December 30, 2008, by and among the Company and
the Series D Investors (the “Series D Investor Rights Agreement”), which governs
certain rights of the Series D Investors, as holders of all of the issued and
outstanding Series D Preferred Stock in the Company (the “Series D Preferred
Stock”), including, but not limited to, the right of the Series D Investors to
participate in future equity offerings by the Company;

WHEREAS, the Series G Investor and the Company are parties to the Series G
Preferred Stock Purchase Agreement dated of even date herewith (“Series G
Purchase Agreement”), and in order to induce the Series G Investor to invest
funds in the Company as contemplated in the Series G Purchase Agreement, the
Company has agreed to grant the Series G Investor certain rights that are
consistent with those granted to the Series D Investors under the Series D
Investors Rights Agreement; and

WHEREAS, the Company, the Series D Investors and the Series G Investor agree to
amend and restated the Series D Investor Rights Agreement in its entirety as set
forth in this Agreement.

NOW, THEREFORE, the parties hereby agree as follows:

 

1. Definitions. For purposes of this Agreement:

 

  1.1 “Affiliate” means, with respect to any specified Person, any other Person
who, directly or indirectly, controls, is controlled by, or is under common
control with such Person, including without limitation any general partner,
managing member, officer or director of such Person or any venture capital fund
now or hereafter existing that is controlled by one or more general partners or
managing members of, or shares the same management company with, such Person.

 

  1.2 “Common Stock” means shares of the Company’s common stock, par value
$0.001 per share.

--------------------------------------------------------------------------------

  1.3 “Derivative Securities” means any securities or rights convertible into,
or exercisable or exchangeable for (in each case, directly or indirectly),
Common Stock, including options and warrants.

 

  1.4 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and
the rules and regulations promulgated thereunder.

 

  1.5 “GAAP” means generally accepted accounting principles in the United
States.

 

  1.6 “Key Employee” means any executive-level employee (including division
director and vice president-level positions) as well as any employee who, either
alone or in concert with others, develops, invents, programs, or designs any
Company Intellectual Property (as defined in the Series G Purchase Agreement).

 

  1.7 “New Securities” means, collectively, equity securities of the Company,
whether or not currently authorized, as well as rights, options, or warrants to
purchase such equity securities, or securities of any type whatsoever that are,
or may become, convertible or exchangeable into or exercisable for such equity
securities.

 

  1.8 “Person” means any individual, corporation, partnership, trust, limited
liability company, association or other entity.

 

  1.9 “Preferred Stock” means, collectively, shares of the Company’s Series A,
B, C, D and G Preferred Stock.

 

  1.10 “SEC” means the Securities and Exchange Commission.

 

  1.11 “Securities Act” means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder.

 

  1.12 “Series C Director” means any director of the Company that the holders of
record of the Series C Preferred Stock are entitled to elect pursuant to the
Company’s Series C Preferred Stock Certificate of Designation.

 

  1.13 “Series D Director” means any director of the Company that the holders of
record of the Series D Preferred Stock are entitled to elect pursuant to the
Company’s Series D Preferred Stock Certificate of Designation.

 

  1.14 “Series D Preferred Stock” means shares of the Company’s Series D
Preferred Stock, par value $0.001 per share.

 

  1.15 “Series G Director” means any director of the Company that the holders of
record of the Series G Preferred Stock are entitled to nominate pursuant to the
Company’s Series G Preferred Stock Certificate of Designation.”

 

2

--------------------------------------------------------------------------------

  1.16 “Series G Preferred Stock” means shares of the Company’s Series G
Preferred Stock, par value $0.001 per share.”

 

2. Rights to Future Stock Issuances.

 

  2.1 Participation Right. If, at any time after the date of this Agreement and
prior to the termination of this participation right pursuant to subsection 2.5,
the Company should desire to issue in a transaction not registered under the
Securities Act any New Securities (as hereinafter defined), it shall give each
Investor the right to purchase such Investor’s pro rata share (or any part
thereof) of all of such privately offered New Securities on the same terms as
the Company is willing to sell such New Securities to any other person, for a
period of thirty (30) calendar days after the initial issuance of such New
Securities. Each such Investor’s pro rata share of the New Securities shall be
equal to that percentage of the outstanding Common Stock of the Company held by
such Investor on the date of delivery of notice to such Investor, as set forth
in Section 2.2 below, of the Company’s intention to sell and issue such New
Securities. For purposes of this subsection 2.1, the outstanding Common Stock of
the Company shall include (i) outstanding shares of Common Stock, and
(ii) shares of Common Stock issued or issuable upon exercise and/or conversion
of any then outstanding options, warrants and Preferred Stock of the Company.

 

  2.2 Notice; Over-Allotment. Promptly after the sale or issuance by the Company
of any New Securities, the Company shall notify in writing each such Investor of
the sale and issuance of such securities, setting forth the terms of such sale.
Within seven (7) days after receipt of such notice, each such Investor shall
notify the Company whether such Investor desires to purchase such Investor’s pro
rata share, or any part thereof, of the New Securities so offered. If such
Investor elects to purchase such Investor’s pro rata share, as applicable, then
such Investor shall have a right of over-allotment such that if any other
Investor fails to purchase such Investor’s pro rata share of the New Securities,
such Investors who have elected to purchase their pro rata shares may purchase,
on a pro rata basis, that portion of the New Securities which such other
Investor(s) elected not to purchase.

 

  2.3 Closing of Investor Purchases. If an Investor gives the Company notice
that such Investor desires to purchase any of the New Securities offered by the
Company, payment for the New Securities shall be by check or wire transfer,
against delivery of the New Securities at the executive offices of the Company
within twenty (20) days after giving the Company such notice. The Company shall
take all such action as may be required by any regulatory authority in
connection with the exercise by such Investor of the right to purchase New
Securities as set forth in this Section 2.

 

  2.4

Exempted Issuances. The participation right contained in this Section 2 shall
not apply to the issuance by the Company of New Securities (i) upon conversion
or

 

3

--------------------------------------------------------------------------------

  exercise of any outstanding securities; (ii) to officers, directors or
employees of, or consultants to, the Company pursuant to a warrant, stock grant,
option agreement or plan, purchase plan or other employee stock incentive
program or agreement approved by the Board of Directors; (iii) in connection
with the acquisition by the Company of another business entity or majority
ownership thereof approved by the Board of Directors; (iv) to lease companies,
real estate lessors, banks or financial institutions, in connection with any
lease or debt financing transaction approved by the Board of Directors; (v) to
purchase equipment or services; (vi) upon exercise of warrants outstanding as of
the date of this Agreement; (vii) in connection with any stock split, stock
dividend, distribution, recapitalization or similar event; (viii) in connection
with a strategic investment and/or acquisition of technology or intellectual
property not principally for equity financing purposes approved by the Board of
Directors; (ix) pursuant to the Series G Purchase Agreement, including without
limitation issuances of shares of Series D Preferred Stock or Series G Preferred
Stock; (x) in any registered offering; or (x) by way of a dividend or other
distribution on New Securities described in the foregoing clauses (i) through
(x).

 

  2.5 Termination. The participation right set forth in this Section 2 shall
terminate and be of no further force and effect upon such time as the Investor
or its affiliates hold less than five (5) shares of Series D Preferred Stock.

 

3. Additional Covenants.

 

  3.1 Insurance. The Company shall use its commercially reasonable efforts to
obtain, within ninety (90) days of the date hereof, from financially sound and
reputable insurers Directors and Officers liability insurance in an amount and
on terms and conditions satisfactory to the Board of Directors, and will use
commercially reasonable efforts to cause such insurance policies to be
maintained until such time as the Board of Directors determines that such
insurance should be discontinued. The policy shall not be cancelable by the
Company without prior approval by the Board of Directors including the Series C,
D and G Directors.

 

  3.2 Employee Agreements. The Company will cause each person now or hereafter
employed by it or by any subsidiary (or engaged by the Company or any subsidiary
as a consultant/independent contractor) with access to confidential information
and/or trade secrets to enter into a nondisclosure and proprietary rights
assignment agreement. In addition, the Company shall not amend, modify,
terminate, waive, or otherwise alter, in whole or in part, any of the
above-referenced agreements or any restricted stock agreement between the
Company and any employee, without the consent of the Board of Directors.

 

4

--------------------------------------------------------------------------------

  3.3 Matters Requiring Investor Director Approval. So long as the holders of
Series D Preferred Stock or Series G Preferred Stock are entitled to elect a
Series D Director or nominate a Series G Director, respectively, the Company
hereby covenants and agrees with each of the Investors that it shall not,
without approval of the Board of Directors, which approval must include the
affirmative vote of the Series C, Series D and Series G Directors:

 

  3.3.1 make, or permit any subsidiary to make, any loan or advance to, or own
any stock or other securities of, any subsidiary or other corporation,
partnership, or other entity unless it is wholly owned (directly or indirectly)
by the Company;

 

  3.3.2 make, or permit any subsidiary to make, any loan or advance to any
Person, including, without limitation, any employee or director of the Company
or any subsidiary, except advances and similar expenditures in the ordinary
course of business or under the terms of an employee stock or option plan
approved by the Board of Directors;

 

  3.3.3 guarantee, directly or indirectly, or permit any subsidiary to
guarantee, directly or indirectly, any indebtedness except for trade accounts of
the Company or any subsidiary arising in the ordinary course of business;

 

  3.3.4 make any investment inconsistent with any investment policy approved by
the Board of Directors;

 

  3.3.5 incur any aggregate indebtedness in excess of $100,000 that is not
already included in a budget approved by the Board of Directors, other than
trade credit incurred in the ordinary course of business;

 

  3.3.6 otherwise enter into or be a party to any transaction with any director,
officer, or employee of the Company or any “associate” (as defined in Rule 12b-2
promulgated under the Exchange Act) of any such person, except for transactions
contemplated by this Agreement, the Series D Purchase Agreement and Series G
Purchase Agreement, and the Employment Agreements; transactions resulting in
payments to or by the Company in an aggregate amount less than $60,000 per year;
or transactions made in the ordinary course of business and pursuant to
reasonable requirements of the Company’s business and upon fair and reasonable
terms that are approved by a majority of the Board of Directors;

 

  3.3.7 increase the compensation of the executive officers, including approving
the creation or amendment of any option plans under which grants or stock awards
may be made to executive officers;

 

  3.3.8 change the principal business of the Company, enter new lines of
business, or exit the current line of business;

 

5

--------------------------------------------------------------------------------

  3.3.9 sell, assign, license, pledge, or encumber material technology or
intellectual property, other than licenses granted in the ordinary course of
business.

 

  3.4 Board Matters. Unless otherwise determined by the vote of a majority of
the directors then in office, the Board of Directors shall meet at least
quarterly in accordance with an agreed-upon schedule. The Company shall
reimburse the nonemployee directors for all reasonable out-of-pocket travel
expenses incurred (consistent with the Company’s travel policy) in connection
with attending meetings of the Board of Directors. Except where prohibited by
applicable law or where required by applicable listing standards or to obtain
the benefit of an applicable rule or regulation (such as Rule 16b-3 or the
exemptions provided under IRC §162(m)), each committee of the Company’s Board of
Directors shall include at least one Series C, Series D or Series G Director.

 

  3.5 Successor Indemnification. If the Company or any of its successors or
assignees consolidates with or merges into any other Person and is not the
continuing or surviving corporation or entity of such consolidation or merger,
then to the extent necessary, proper provision shall be made so that the
successors and assignees of the Company assume the obligations of the Company
with respect to indemnification of members of the Board of Directors as in
effect immediately before such transaction, whether such obligations are
contained in the Company’s Bylaws, its Certificate of Incorporation, or
elsewhere, as the case may be.

 

4. Miscellaneous.

 

  4.1 Successors and Assigns. The rights under this Agreement may be assigned
(but only with all related obligations) by an Investor without the Company’s
consent, so long as the assignee acquires the Investor’s ownership interest in
the Company.

 

  4.2 Governing Law. This Agreement shall be governed by, and construed in
accordance with, the laws of the State of Delaware, regardless of the laws that
might otherwise govern under applicable principles of conflicts of law.

 

  4.3 Counterparts; Facsimile. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. This Agreement may also
be executed and delivered by facsimile signature and in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

 

  4.4 Titles and Subtitles. The titles and subtitles used in this Agreement are
for convenience only and are not to be considered in construing or interpreting
this Agreement.

 

6

--------------------------------------------------------------------------------

  4.5 Notices. Any notice required or permitted hereunder shall be given in
writing and shall be deemed effectively given upon personal delivery and if a
fax number has been provided, upon delivery (with answerback confirmed),
addressed to a party at its address and the fax number, if any, shown below or
at such other address and fax number as such party may designate by three days
advance notice to the other party.

Any notice to the Investor shall be sent to the addresses set forth on Schedule
A, with a copy to:

McLane, Graf, Raulerson & Middleton, Professional Association

900 Elm Street

P.O. Box 326

Manchester, NH 03105-0326

Attention: Thomas W. Hildreth, Esquire

Telephone: 603-628-1177

Fax: 603-625-5650

Any notice to the Company shall be sent to:

International Stem Cell Corporation

2595 Jason Court

Oceanside, CA 92056

Telephone: 760-940-6383

Fax: 760-940-6387

with a copy to:

DLA Piper US LLP

4365 Executive Drive, Suite 1100

San Diego, California 92121-2133

Attention: Douglas J. Rein, Esquire

Telephone: 858-677-1443

Fax: 858-638-5043

 

  4.6 Amendments and Waivers. Any term of this Agreement may be amended and the
observance of any term of this Agreement may be waived (either generally or in a
particular instance, and either retroactively or prospectively) only with the
written consent of the Investors holding a majority in interest of the Series D
Preferred Stock and Series G Preferred Stock, voting together, then outstanding.
Notwithstanding the foregoing, this Agreement may not be amended or terminated
and the observance of any term hereof may not be waived with respect to any
Investor without the written consent of such Investor, unless such amendment,
termination, or waiver applies to all Investors in the same fashion. No waivers
of or exceptions to any term, condition, or provision of this Agreement, in any
one or more instances, shall be deemed to be or construed as a further or
continuing waiver of any such term, condition, or provision.

 

7

--------------------------------------------------------------------------------

  4.7 Severability. In case any one or more of the provisions contained in this
Agreement is for any reason held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality, or unenforceability shall not affect any
other provision of this Agreement, and such invalid, illegal, or unenforceable
provision shall be reformed and construed so that it will be valid, legal, and
enforceable to the maximum extent permitted by law.

 

  4.8 Additional Investors. Notwithstanding anything to the contrary contained
herein, if the Company issues additional shares of the Company’s Series D
Preferred Stock or Series G Preferred Stock after the date hereof, whether
pursuant to the Series D Purchase Agreement or Series G Purchase Agreement, or
otherwise, any purchaser of such shares of Series D Preferred Stock or Series G
Preferred Stock may become a party to this Agreement by executing and delivering
an additional counterpart signature page to this Agreement, and thereafter shall
be deemed an “Investor” for all purposes hereunder. No action or consent by the
Investors shall be required for such joinder to this Agreement by such
additional Investor, so long as such additional Investor has agreed in writing
to be bound by all of the obligations as an “Investor” hereunder.

 

  4.9 Entire Agreement. This Agreement (including any Schedules and Exhibits
hereto) constitutes the full and entire understanding and agreement among the
parties with respect to the subject matter hereof, and any other written or oral
agreement relating to the subject matter hereof existing between the parties is
expressly canceled.

 

  4.10 Termination. This Agreement shall terminate at such time as there no
longer are any shares of Series D Preferred Stock and Series G Preferred Stock
remain outstanding.

[Signature page follows.]

 

8

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first written above.

 

INTERNATIONAL STEM CELL CORPORATION By:  

/s/ Kurt May

Name: Kurt May

Title: President

INVESTOR: AR Partners, LLC By:  

/s/ Ruslan Semechkin

Name: Ruslan Semechkin

Title: Manager

/s/ Andrey Semechkin

Andrey Semechkin

/s/ Ruslan Semechkin

Ruslan Semechkin

X-Master, Inc. By:  

/s/ Ruslan Semechkin

Name: Ruslan Semechkin

Title: President

[Signature page for Investors’ Rights Agreement]

--------------------------------------------------------------------------------

SCHEDULE A

Investors

Series D Investors

Andrey Semechkin

1 Overlook Drive, #11

Amherst, NH 03031

Ruslan Semechkin

1 Overlook Drive, #11

Amherst, NH 03031

X-Master, Inc.

1 Overlook Drive, #11

Amherst, NH 03031

Series G Investor

AR Partners, LLC

5950 Priestly Drive

Carlsbad, CA 92008